Mitsuhiro Rokuda

1.0k total citations
19 papers, 821 citations indexed

About

Mitsuhiro Rokuda is a scholar working on Rheumatology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Mitsuhiro Rokuda has authored 19 papers receiving a total of 821 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Rheumatology, 9 papers in Pathology and Forensic Medicine and 7 papers in Genetics. Recurrent topics in Mitsuhiro Rokuda's work include Rheumatoid Arthritis Research and Therapies (10 papers), Lymphoma Diagnosis and Treatment (9 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Mitsuhiro Rokuda is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (10 papers), Lymphoma Diagnosis and Treatment (9 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Mitsuhiro Rokuda collaborates with scholars based in Japan, South Korea and Taiwan. Mitsuhiro Rokuda's co-authors include Tetsuya Iida, Takeshi Honda, Takahiro Ono, Myoung Ho Jang, Kwon-Sam Park, Kazuhisa Okada, Yoshiya Tanaka, Yuichiro Kaneko, Tsutomu Takeuchi and Satoshi Ushijima and has published in prestigious journals such as Infection and Immunity, Annals of the Rheumatic Diseases and Arthritis Research & Therapy.

In The Last Decade

Mitsuhiro Rokuda

18 papers receiving 809 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mitsuhiro Rokuda Japan	9	520	404	210	141	121	19	821
Rosa Collado Spain	17	95 0.2×	187 0.5×	18 0.1×	41 0.3×	210 1.7×	36	630
Garry M. Marley United States	11	164 0.3×	104 0.3×	45 0.2×	43 0.3×	170 1.4×	11	641
Chad K. Heazlewood Australia	6	17 0.0×	194 0.5×	15 0.1×	60 0.4×	323 2.7×	7	699
Helit Cohen Israel	13	89 0.2×	50 0.1×	9 0.0×	146 1.0×	205 1.7×	17	445
Lori A. Wagner United States	10	15 0.0×	118 0.3×	108 0.5×	114 0.8×	254 2.1×	16	704
Kaoruko Katsura Japan	6	105 0.2×	37 0.1×	15 0.1×	34 0.2×	57 0.5×	18	356
Nicolas Stocker France	9	40 0.1×	97 0.2×	11 0.1×	22 0.2×	125 1.0×	26	360
Jihoon Chang United States	11	55 0.1×	346 0.9×	8 0.0×	43 0.3×	132 1.1×	13	574
Bidossessi Wilfried Hounkpe Brazil	9	27 0.1×	84 0.2×	36 0.2×	11 0.1×	205 1.7×	29	417
Nabila Ibnou-Zekri Switzerland	12	9 0.0×	376 0.9×	158 0.8×	124 0.9×	187 1.5×	17	612

Countries citing papers authored by Mitsuhiro Rokuda

Since Specialization

Citations

This map shows the geographic impact of Mitsuhiro Rokuda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitsuhiro Rokuda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitsuhiro Rokuda more than expected).

Fields of papers citing papers by Mitsuhiro Rokuda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mitsuhiro Rokuda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitsuhiro Rokuda. The network helps show where Mitsuhiro Rokuda may publish in the future.

Co-authorship network of co-authors of Mitsuhiro Rokuda

This figure shows the co-authorship network connecting the top 25 collaborators of Mitsuhiro Rokuda. A scholar is included among the top collaborators of Mitsuhiro Rokuda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mitsuhiro Rokuda. Mitsuhiro Rokuda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Kashiwagi, Atsunori, et al.. (2023). Healthcare resource utilization and healthcare costs in patients with type 2 diabetes mellitus initiating sodium‐glucose cotransporter 2 inhibitors vs dipeptidyl peptidase‐4 inhibitors in Japan: A real‐world administrative database analysis. Journal of Diabetes Investigation. 15(3). 374–387.

Takahashi, Hirokazu, et al.. (2023). Comparative effectiveness of sodium‐glucose co‐transporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors on liver function in patients with type 2 diabetes in Japan: A real‐world data analysis. Diabetes Obesity and Metabolism. 26(3). 997–1007. 5 indexed citations

Abiru, Norio, et al.. (2022). Demographic and clinical characteristics of patients with type 1 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors in Japan: A real-world administrative database analysis. Diabetes Research and Clinical Practice. 190. 109973–109973. 3 indexed citations

Tanaka, Yoshiya, Tsutomu Takeuchi, Daisuke Kato, et al.. (2022). Post hoc analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4). Modern Rheumatology. 33(1). 73–80. 4 indexed citations

Kashiwagi, Atsunori, et al.. (2022). Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium–glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase‐4 inhibitor: A real‐world administrative database study in Japan. Journal of Diabetes Investigation. 14(3). 404–416. 4 indexed citations

Tanaka, Yoshiya, Tsutomu Takeuchi, Yuichiro Kaneko, et al.. (2021). Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis. Arthritis Research & Therapy. 23(1). 221–221. 9 indexed citations

Takeuchi, Tsutomu, Yoshiya Tanaka, Sakae Tanaka, et al.. (2021). Safety and Effectiveness of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis: Final Results (32 Months of Mean Peficitinib Treatment) From a Long-Term, Open-Label Extension Study in Japan, Korea, and Taiwan. Rheumatology and Therapy. 8(1). 425–442. 17 indexed citations

Tanaka, Yoshiya, et al.. (2021). A pooled analysis of serious infections and herpes zoster-related disease in Asian patients with rheumatoid arthritis treated with peficitinib (ASP015K) over a median of 3 years. Modern Rheumatology. 32(4). 708–717. 3 indexed citations

Takeuchi, Tsutomu, Yoshiya Tanaka, Sakae Tanaka, et al.. (2020). Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan. Arthritis Research & Therapy. 22(1). 155–155. 22 indexed citations

10.

Takeuchi, Tsutomu, et al.. (2020). A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years. Modern Rheumatology. 31(3). 543–555. 10 indexed citations

11.

Takeuchi, Tsutomu, Yoshiya Tanaka, Sakae Tanaka, et al.. (2019). Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Annals of the Rheumatic Diseases. 78(10). 1305–1319. 101 indexed citations

12.

Tanaka, Yoshiya, Tsutomu Takeuchi, Sakae Tanaka, et al.. (2019). Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3). Annals of the Rheumatic Diseases. 78(10). 1320–1332. 85 indexed citations

13.

Tanaka, Yoshiya, Tsutomu Takeuchi, Sakae Tanaka, et al.. (2019). FRI0134 A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF PEFICITINIB (ASP015K) IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO HAD AN INADEQUATE RESPONSE TO DMARDS. Annals of the Rheumatic Diseases. 78. 736–737. 1 indexed citations

14.

Tanaka, Yoshiya, et al.. (2019). FRI0165 PATIENT- AND PHYSICIAN-REPORTED OUTCOMES FROM RAJ4: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF PEFICITINIB (ASP015K) IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) WHO HAD AN INADEQUATE RESPONSE TO METHOTREXATE (MTX). Annals of the Rheumatic Diseases. 78. 756–756. 1 indexed citations

15.

Takeuchi, Tsutomu, Yoshiya Tanaka, Sakae Tanaka, et al.. (2019). OP0026 A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF PEFICITINIB (ASP015K) IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO HAD AN INADEQUATE RESPONSE TO METHOTREXATE. Annals of the Rheumatic Diseases. 78. 81–82. 1 indexed citations

16.

Rokuda, Mitsuhiro, et al.. (2018). Identification of Drug Characteristics for Implementing Multiregional Clinical Trials Including Japan. Clinical Therapeutics. 40(2). 284–295. 8 indexed citations

17.

Kodama, Toshio, Mitsuhiro Rokuda, Kwon-Sam Park, et al.. (2007). Identification and characterization of VopT, a novel ADP-ribosyltransferase effector protein secreted via the Vibrio parahaemolyticus type III secretion system 2. Cellular Microbiology. 9(11). 2598–2609. 104 indexed citations

18.

Ono, Takahiro, et al.. (2004). Cytotoxicity and Enterotoxicity of the Thermostable Direct Hemolysin‐Deletion Mutants of Vibrio parahaemolyticus. Microbiology and Immunology. 48(4). 313–318. 109 indexed citations

19.

Park, Kwon-Sam, Takahiro Ono, Mitsuhiro Rokuda, et al.. (2004). Functional Characterization of Two Type III Secretion Systems of Vibrio parahaemolyticus. Infection and Immunity. 72(11). 6659–6665. 334 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact